Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

Is­sues with a de­liv­ery de­vice are slow­ing down Re­genxBio’s clin­i­cal plans for one of its lead gene ther­a­pies.

In its Q3 up­date, Re­genxBio in­formed in­vestors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER